Gilead Sciences Receives Additional Approval for Trodelvy in HR+/HER2- Breast Cancer Treatment Gilead Sciences has secured additional approval for Trodelvy as a treatment for patients with HR+/HER2- breast cancer with a history of chemotherapy. This represents a significant advancement in oncology care.

Gilead Sciences Receives Additional Approval for Trodelvy in HR+/HER2- Breast Cancer Treatment #Japan #Tokyo #Trodelvy #Gilead_Sciences #HR+/HER2-

Gilead Submits Approval Application for Trodelvy in Treating HR-/HER2- Breast Cancer Gilead Sciences has filed for expanded approval of Trodelvy for use in HR-/HER2- breast cancer, marking a significant advancement in treatment options.

Gilead Submits Approval Application for Trodelvy in Treating HR-/HER2- Breast Cancer #Japan #Tokyo #Breast_Cancer #Trodelvy #Gilead_Sciences

New Combination Therapy for PD-L1 Positive TNBC Shows Promising Results in Clinical Trial Published in NEJM The combination of Trodelvy and Keytruda could become a new standard for treating patients with PD-L1 positive metastatic triple-negative breast cancer, as per the phase III trial results.

New Combination Therapy for PD-L1 Positive TNBC Shows Promising Results in Clinical Trial Published in NEJM #USA #TNBC #Foster_City #KEYTRUDA #Trodelvy

Marengo Therapeutics Shares Promising Results on Cancer Therapy at 2025 Conference Marengo Therapeutics presents early findings on the combination of Invikafusp Alfa and TRODELVY® for breast cancer, showing promising results in terms of safety and anti-tumor activity.

Marengo Therapeutics Shares Promising Results on Cancer Therapy at 2025 Conference #United_States #Cambridge #Marengo_Therapeutics #Invikafusp_Alfa #Trodelvy

Gilead Announces Latest Findings from Phase III ASCENT-07 Trial for Breast Cancer Treatment On November 7, Gilead Sciences revealed new data from the ASCENT-07 trial, which evaluates Trodelvy in breast cancer treatments, noting it didn't meet primary endpoints yet showed promising trends.

Gilead Announces Latest Findings from Phase III ASCENT-07 Trial for Breast Cancer Treatment #USA #Foster_City #Gilead #Trodelvy #ASCENT-07

Gilead Sciences Reports Strong Q3 2025 Earnings with Product Sales Growth Gilead Sciences has reported its Q3 2025 earnings, showcasing a 4% increase in product sales excluding Veklury, highlighting a robust pipeline with anticipated growth.

Gilead Sciences Reports Strong Q3 2025 Earnings with Product Sales Growth #United_States #Foster_City #Trodelvy #Gilead_Sciences #Veklury

Trodelvy Shows Promise in Treating Metastatic Triple-Negative Breast Cancer by Reducing Risks Recent results from the ASCENT-03 trial reveal that Trodelvy significantly reduces disease progression and death risks in TNBC patients compared to chemotherapy.

Trodelvy Shows Promise in Treating Metastatic Triple-Negative Breast Cancer by Reducing Risks #USA #TNBC #Foster_City #Trodelvy #Gilead_Sciences

Gilead and Kite Strengthen Cancer Treatment Innovations Ahead of ESMO 2025 Gilead and Kite will unveil groundbreaking cancer treatment data at ESMO 2025, highlighting advancements in therapies for triple-negative breast cancer and gastric cancer.

Gilead and Kite Strengthen Cancer Treatment Innovations Ahead of ESMO 2025 #United_States #Foster_City #Gilead #Trodelvy #Kite

Delayed TNBC readout for Datroway delivers survival benefit AstraZeneca and Daiichi Sankyo's Datroway comes good in the delayed TROPION-Breast02 trial as a frontline triple-negative breast cancer treatment.

#breastcancer #triplenegativebreastcancer #TNBC #AstraZeneca #AZ #Datroway #datopotamabderuxtecan #DaiichiSankyo #Oncology #TNBCpatients #TROPIONBreast02trial #metastaticTNBC #immunotherapy #TNBCtumours #Gilead #TROP2ADC #Trodelvy #sacituzumabgovitecan #PFSdata
zurl.co/t8A6T

Marengo Therapeutics Progresses STARt-002 Trial for Metastatic Breast Cancer Treatment Marengo Therapeutics announces the progress of its STARt-002 clinical trial, which evaluates the promising invikafusp alfa treatment for metastatic breast cancer patients.

Marengo Therapeutics Progresses STARt-002 Trial for Metastatic Breast Cancer Treatment #United_States #Cambridge #Marengo_Therapeutics #Trodelvy #STARt-002

IDEAYA Biosciences Presents Positive Phase 1/2 Trial Results for IDE397 and Trodelvy in Rare Urothelial Cancer IDEAYA Biosciences reports promising results from a Phase 1/2 trial involving IDE397 and Trodelvy for patients with MTAP-deletion urothelial cancer. The study shows positive response rates, paving the way for further investigations.

IDEAYA Biosciences Presents Positive Phase 1/2 Trial Results for IDE397 and Trodelvy in Rare Urothelial Cancer #United_States #IDEAYA_Biosciences #South_San_Francisco #Trodelvy #IDE397

IDEAYA Biosciences Enrolls First Patient in Clinical Trial for Innovative Lung Cancer Treatment IDEAYA Biosciences has begun a Phase 1/2 trial for IDE397 and Trodelvy in non-small cell lung cancer, targeting MTAP-deletion solid tumors with no current therapies.

IDEAYA Biosciences Enrolls First Patient in Clinical Trial for Innovative Lung Cancer Treatment #United_States #IDEAYA_Biosciences #South_San_Francisco #NSCLC #Trodelvy

Trodelvy and Keytruda Reduce Progression and Mortality Risk in TNBC Trodelvy and Keytruda combination therapy reduces progression and mortality risk by 35% in PD-L1 positive metastatic TNBC, proving its potential as a new standard treatment.

Trodelvy and Keytruda Reduce Progression and Mortality Risk in TNBC #United_States #California #TNBC #KEYTRUDA #Trodelvy

Trodelvy Shows Significant PFS Improvement for TNBC Treatment Gilead's Trodelvy demonstrates noteworthy progression-free survival improvements in triple-negative breast cancer, paving new treatment paths.

Trodelvy Shows Significant PFS Improvement for TNBC Treatment #United_States #Breast_Cancer #NIH #Foster_City #Trodelvy

New research from #ASCO25 points to a potential shift in first-line treatment for metastatic TNBC.

People with PD-L1+ TNBC had better outcomes with Trodelvy + Keytruda than with chemo + Keytruda.

Details here 🔗 bit.ly/ASCO_2025
#MetastaticBreastCancer #TNBC #CancerResearch #Trodelvy #Keytruda

Gilead’s Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial (Reuters) -Gilead Sciences’ Trodelvy in combination with Merck (NSE:PROR)’s blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, according to results of a large trial presented on Saturday. The data is likely to change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert said. After a median follow-up of 14 months, patients treated with Trodelvy, a so-called antibody-drug conjugate, and Keytruda went 11.2 months without their cancer progressing, a measure known as progress-free survival. That compared with PFS of 7.8 months for those given the standard treatment of chemotherapy and Keytruda, researchers said. Patients given the Trodelvy/Keytruda combination responded to the treatment for a median of 16.5 months, compared with 9.2 months for the chemo group, according to full results of the study presented at the American Society of Clinical Oncology scientific meeting in Chicago. The researchers said patients are still being followed to see if the regimen has an impact on overall survival. Gilead (NASDAQ:GILD) previously said the Phase 3 study in 443 patients with advanced triple-negative breast cancer whose tumors express PD-L1 - the protein targeted by drugs like Keytruda - had met its goal. The findings suggest that the combination of Trodelvy and Keytruda "will likely become a new front-line standard of care in this setting,” Dr. Jane Lowe Meisel, co-director of breast oncology at Emory University School of Medicine and a designated ASCO expert said in a statement. ASCO estimates that about 10% of breast cancers in the United States are triple-negative. That tends to be more difficult to treat than hormone-sensitive subtypes, because it does not have the common biomarkers used to guide treatment, the tumors are often larger, and the recurrence rate is high. The medical group said that about 40% of triple-negative breast cancers are also PD-L1 positive, making them candidates for Keytruda. Antibody-drug conjugates like Trodelvy are designed to deliver an anti-cancer drug more precisely to malignant cells, causing less damage to healthy cells than chemotherapy. Serious side effects for Trodelvy included neutropenia, a condition caused by cancer treatments that lower levels of infection-fighting white blood cells, reported in 43% of patients, and diarrhea in 10%. In the chemotherapy group, the incidence of neutropenia was 45%, while 16% of patients had anemia and 14% had low blood platelet counts. Trodelvy is already approved for patients with advanced triple-negative breast cancer who had two or more prior therapies, and for previously treated hormone-receptor-positive, HER2-negative metastatic breast cancer. Gilead is conducting several other Trodelvy studies, including a trial of the drug as an initial treatment for triple-negative breast cancer patients who do not express PD-L1.

Click Subscribe #BreastCancer #CancerResearch #Trodelvy #Keytruda #ClinicalTrial

📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌

Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.

#Onco404 #Cancer #Kanser #MedSky #AntibodyDrugConjugate #ADC #Enhertu #Trodelvy #Padcev #Kadcyla #Elahere #Mylotarg #Polivy #Vocabulary

Significant Improvement in PFS for Untreated PD-L1 Positive TNBC Using Trodelvy and Keytruda Cohabulary Trodelvy and Keytruda's combination shows statistically significant improvement in progression-free survival for untreated PD-L1 positive metastatic triple-negative breast cancer patients, marking a potential treatment revolution.

Significant Improvement in PFS for Untreated PD-L1 Positive TNBC Using Trodelvy and Keytruda Cohabulary #United_States #TNBC #Foster_City #KEYTRUDA #Trodelvy

Gilead Sciences Reports Strong Q1 2025 Performance Igniting Future Growth Prospects Gilead Sciences posts robust Q1 2025 results, showcasing sales growth across key products and positive trial outcomes that signal bright prospects ahead.

Gilead Sciences Reports Strong Q1 2025 Performance Igniting Future Growth Prospects #USA #Foster_City #Trodelvy #Gilead_Sciences #Veklury

Marengo Therapeutics Initiates Clinical Trial with Invikafusp Alfa and Trodelvy for Breast Cancer Marengo Therapeutics has initiated its STARt-002 trial for metastatic breast cancer, assessing the innovative Invikafusp Alfa alongside Trodelvy®, aiming to expand immunotherapy options.

Marengo Therapeutics Initiates Clinical Trial with Invikafusp Alfa and Trodelvy for Breast Cancer #USA #Cambridge #Marengo_Therapeutics #Invikafusp_Alfa #Trodelvy

Trodelvy Plus Keytruda Improves Progression-Free Survival in PD-L1+ mTNBC, Phase III Data Show | Docwire News Trodelvy plus Keytruda improves PFS in first-line PD-L1+ mTNBC, marking a first for a TROP-2 ADC-immunotherapy combination.

New phase III data show Trodelvy plus Keytruda significantly improves progression-free survival in PD-L1+ metastatic TNBC.
Learn more: www.docwirenews.com/post/trodelv...

#BreastCancer #mTNBC #Trodelvy #Keytruda #OncologyResearch

Gilead Seeks Approval for Trodelvy in Advanced Breast Cancer Treatment Gilead Sciences has submitted an additional approval request for Trodelvy, targeting patients with advanced HR+/HER2- breast cancer, enhancing treatment options.

Gilead Seeks Approval for Trodelvy in Advanced Breast Cancer Treatment #Japan #Tokyo #Trodelvy #Gilead_Sciences #HR+/HER2-

Trodelvy-Keytruda pairing hits the spot in breast cancer Gilead has cemented the role of its TROP2 drug Trodelvy in triple-negative breast cancer with a study win in combination with MSD's Keytruda.

News Catch-Up: Yesterday, #GileadSciences cemented the role of its TROP2 drug #Trodelvy in triple-negative breast cancer (TNBC) with a win in a phase 3 combination trial with MSD's PD-1 inhibitor Keytruda.

IDEAYA Biosciences Expands Phase 1/2 Study for Innovative Cancer Treatment with IDE397 and Trodelvy® IDEAYA Biosciences has commenced expanded Phase 1/2 trials for IDE397 combined with Trodelvy® to treat MTAP-deletion urothelial cancer, addressing significant medical needs.

IDEAYA Biosciences Expands Phase 1/2 Study for Innovative Cancer Treatment with IDE397 and Trodelvy® #United_States #IDEAYA_Biosciences #South_San_Francisco #Trodelvy #IDE397

IDEAYA Biosciences and Gilead Join Forces for Promising Clinical Study on NSCLC Treatment IDEAYA Biosciences has partnered with Gilead Sciences to evaluate the promising combination therapy involving IDE397 and Trodelvy for NSCLC patients. This collaboration aims to address MTAP deletions.

IDEAYA Biosciences and Gilead Join Forces for Promising Clinical Study on NSCLC Treatment #United_States #South_San_Francisco #IDEAYA #Gilead #Trodelvy

Eens zien of Agema nu als minister ook zo stoer is om #Trodelvy in het basispakket op te nemen, net als toen ze destijds stond te tetteren als kamerlid. #dekwestie

99 682 personnes ont signé cette pétition et l'ont aidée à aboutir. Cancer du sein triple négatif : donnez-nous accès aux traitements pour rester en vie !

Laboratoire GILEAD Sciences: Appel pour LA VIE : Cancer sein Triple Négatif métastatique, accès au #TRODELVY sans délai - Signez la pétition !via @ChangeFrance

chng.it/LmcbNJVc